Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Peng Jiang, Shengqing Gu, Deng Pan, Jingxin Fu, Avinash Sahu, Xihao Hu, Ziyi Li, Nicole Traugh, Xia Bu, Bo Li, Jun Liu, Gordon J. Freeman, Myles A. Brown, Kai W. Wucherpfennig, X. Shirley Liu

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we developed TIDE, a computational method to model two primary mechanisms of tumor immune evasion: the induction of T cell dysfunction in tumors with high infiltration of cytotoxic T lymphocytes (CTL) and the prevention of T cell infiltration in tumors with low CTL level. We identified signatures of T cell dysfunction from large tumor cohorts by testing how the expression of each gene in tumors interacts with the CTL infiltration level to influence patient survival. We also modeled factors that exclude T cell infiltration into tumors using expression signatures from immunosuppressive cells. Using this framework and pre-treatment RNA-Seq or NanoString tumor expression profiles, TIDE predicted the outcome of melanoma patients treated with first-line anti-PD1 or anti-CTLA4 more accurately than other biomarkers such as PD-L1 level and mutation load. TIDE also revealed new candidate ICB resistance regulators, such as SERPINB9, demonstrating utility for immunotherapy research.

Original languageEnglish (US)
Pages (from-to)1550-1558
Number of pages9
JournalNature Medicine
Volume24
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

T-cells
Immunotherapy
Tumors
T-Lymphocytes
Infiltration
Cytotoxic T-Lymphocytes
Neoplasms
Tumor Escape
TCF Transcription Factors
Oncology
Biomarkers
Immunosuppressive Agents
Computational methods
Melanoma
Therapeutics
Genes
RNA
Gene Expression
Mutation
Survival

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., ... Liu, X. S. (2018). Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine, 24(10), 1550-1558. https://doi.org/10.1038/s41591-018-0136-1

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. / Jiang, Peng; Gu, Shengqing; Pan, Deng; Fu, Jingxin; Sahu, Avinash; Hu, Xihao; Li, Ziyi; Traugh, Nicole; Bu, Xia; Li, Bo; Liu, Jun; Freeman, Gordon J.; Brown, Myles A.; Wucherpfennig, Kai W.; Liu, X. Shirley.

In: Nature Medicine, Vol. 24, No. 10, 01.10.2018, p. 1550-1558.

Research output: Contribution to journalArticle

Jiang, P, Gu, S, Pan, D, Fu, J, Sahu, A, Hu, X, Li, Z, Traugh, N, Bu, X, Li, B, Liu, J, Freeman, GJ, Brown, MA, Wucherpfennig, KW & Liu, XS 2018, 'Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response', Nature Medicine, vol. 24, no. 10, pp. 1550-1558. https://doi.org/10.1038/s41591-018-0136-1
Jiang, Peng ; Gu, Shengqing ; Pan, Deng ; Fu, Jingxin ; Sahu, Avinash ; Hu, Xihao ; Li, Ziyi ; Traugh, Nicole ; Bu, Xia ; Li, Bo ; Liu, Jun ; Freeman, Gordon J. ; Brown, Myles A. ; Wucherpfennig, Kai W. ; Liu, X. Shirley. / Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. In: Nature Medicine. 2018 ; Vol. 24, No. 10. pp. 1550-1558.
@article{8390dcfd7bb84d78b69f539fbb9631d6,
title = "Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response",
abstract = "Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we developed TIDE, a computational method to model two primary mechanisms of tumor immune evasion: the induction of T cell dysfunction in tumors with high infiltration of cytotoxic T lymphocytes (CTL) and the prevention of T cell infiltration in tumors with low CTL level. We identified signatures of T cell dysfunction from large tumor cohorts by testing how the expression of each gene in tumors interacts with the CTL infiltration level to influence patient survival. We also modeled factors that exclude T cell infiltration into tumors using expression signatures from immunosuppressive cells. Using this framework and pre-treatment RNA-Seq or NanoString tumor expression profiles, TIDE predicted the outcome of melanoma patients treated with first-line anti-PD1 or anti-CTLA4 more accurately than other biomarkers such as PD-L1 level and mutation load. TIDE also revealed new candidate ICB resistance regulators, such as SERPINB9, demonstrating utility for immunotherapy research.",
author = "Peng Jiang and Shengqing Gu and Deng Pan and Jingxin Fu and Avinash Sahu and Xihao Hu and Ziyi Li and Nicole Traugh and Xia Bu and Bo Li and Jun Liu and Freeman, {Gordon J.} and Brown, {Myles A.} and Wucherpfennig, {Kai W.} and Liu, {X. Shirley}",
year = "2018",
month = "10",
day = "1",
doi = "10.1038/s41591-018-0136-1",
language = "English (US)",
volume = "24",
pages = "1550--1558",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

AU - Jiang, Peng

AU - Gu, Shengqing

AU - Pan, Deng

AU - Fu, Jingxin

AU - Sahu, Avinash

AU - Hu, Xihao

AU - Li, Ziyi

AU - Traugh, Nicole

AU - Bu, Xia

AU - Li, Bo

AU - Liu, Jun

AU - Freeman, Gordon J.

AU - Brown, Myles A.

AU - Wucherpfennig, Kai W.

AU - Liu, X. Shirley

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we developed TIDE, a computational method to model two primary mechanisms of tumor immune evasion: the induction of T cell dysfunction in tumors with high infiltration of cytotoxic T lymphocytes (CTL) and the prevention of T cell infiltration in tumors with low CTL level. We identified signatures of T cell dysfunction from large tumor cohorts by testing how the expression of each gene in tumors interacts with the CTL infiltration level to influence patient survival. We also modeled factors that exclude T cell infiltration into tumors using expression signatures from immunosuppressive cells. Using this framework and pre-treatment RNA-Seq or NanoString tumor expression profiles, TIDE predicted the outcome of melanoma patients treated with first-line anti-PD1 or anti-CTLA4 more accurately than other biomarkers such as PD-L1 level and mutation load. TIDE also revealed new candidate ICB resistance regulators, such as SERPINB9, demonstrating utility for immunotherapy research.

AB - Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we developed TIDE, a computational method to model two primary mechanisms of tumor immune evasion: the induction of T cell dysfunction in tumors with high infiltration of cytotoxic T lymphocytes (CTL) and the prevention of T cell infiltration in tumors with low CTL level. We identified signatures of T cell dysfunction from large tumor cohorts by testing how the expression of each gene in tumors interacts with the CTL infiltration level to influence patient survival. We also modeled factors that exclude T cell infiltration into tumors using expression signatures from immunosuppressive cells. Using this framework and pre-treatment RNA-Seq or NanoString tumor expression profiles, TIDE predicted the outcome of melanoma patients treated with first-line anti-PD1 or anti-CTLA4 more accurately than other biomarkers such as PD-L1 level and mutation load. TIDE also revealed new candidate ICB resistance regulators, such as SERPINB9, demonstrating utility for immunotherapy research.

UR - http://www.scopus.com/inward/record.url?scp=85052583273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052583273&partnerID=8YFLogxK

U2 - 10.1038/s41591-018-0136-1

DO - 10.1038/s41591-018-0136-1

M3 - Article

VL - 24

SP - 1550

EP - 1558

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 10

ER -